Stella PharmaSTELLA PHARMA CORPORATION4888東証グロース医薬品FY ending Mar 2026, non-consolidated, J-GAAP

Stella Pharma FY ending Mar 2022 results

Stella Pharma brought in ¥100.1M in revenue.

It lost about ¥741 for every ¥100 of sales at the operating level.

Revenue changed -51.4% from the prior year.

What changed from last year

FY ending Mar 2021 → FY ending Mar 2022

Revenue
-51.4%¥206M → ¥100.1M
Gross profit
-53.3%¥181.8M → ¥84.9M
Operating income
Loss-¥680.6M → -¥741.9M
Operating cash flow
Loss-¥772.8M → -¥1.08B
Free cash flow
Loss-¥795.3M → -¥1.13B

Where the money goes

FY ending Mar 2021 → FY ending Mar 2022

Where ¥100 of sales goes

For every ¥100 Stella Pharma sells, how much goes where, and how much is kept.

FY ending Mar 2022
Cost of sales
¥15
SG&A
¥826
Operating loss
¥741
Net loss
¥767

Annual margin trends

Gross margin84.8%
FY ending Mar 2021: 88.3%88.3%FY ending Mar 2022: 84.8%84.8%FY21FY22
Operating margin-741.2%
FY ending Mar 2021: -330.4%-330.4%FY ending Mar 2022: -741.2%-741.2%FY21FY22
Net margin-767.0%
FY ending Mar 2021: -320.1%-320.1%FY ending Mar 2022: -767.0%-767.0%FY21FY22

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Sources

Show source documents (6)
  • EDINET (FSA Japan)

    有価証券報告書-第19期(2025/04/01-2026/03/31)

    ID S100YDYN2026-06-23Open
  • EDINET (FSA Japan)

    有価証券報告書-第18期(2024/04/01-2025/03/31)

    ID S100W6ZM2025-06-26Open
  • EDINET (FSA Japan)

    有価証券報告書-第17期(2023/04/01-2024/03/31)

    ID S100TW8I2024-06-28Open
  • EDINET (FSA Japan)

    有価証券報告書-第16期(2022/04/01-2023/03/31)

    ID S100R76K2023-06-28Open
  • EDINET (FSA Japan)

    有価証券報告書-第15期(令和3年4月1日-令和4年3月31日)

    ID S100OKWQ2022-06-30Open
  • EDINET (FSA Japan)

    有価証券報告書-第14期(令和2年4月1日-令和3年3月31日)

    ID S100LUIT2021-06-30Open

Extracted from XBRL: 38 / Derived from other figures: 2

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.